MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines

SIMPLE SUMMARY: Since 2005, temozolomide (TMZ) has been used as a standard first-line treatment for glioblastoma (GBM, grade IV glioma), and despite many studies and efforts no better alternatives have emerged. Tumor recurrences and TMZ resistance are common and the prognosis is very poor with a med...

Descripción completa

Detalles Bibliográficos
Autores principales: Malacrida, Alessio, Di Domizio, Alessandro, Bentivegna, Angela, Cislaghi, Giacomo, Messuti, Eleonora, Tabano, Silvia Maria, Giussani, Carlo, Zuliani, Valentina, Rivara, Mirko, Nicolini, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772739/
https://www.ncbi.nlm.nih.gov/pubmed/35053068
http://dx.doi.org/10.3390/biology11010070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8772739/
https://www.ncbi.nlm.nih.gov/pubmed/35053068
http://dx.doi.org/10.3390/biology11010070

Ejemplares similares